Company
LON:AZN
AstraZeneca is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease. AstraZeneca has over 67,000 empolyees and operates in over 100 countries with growing presence in important emerging markets.
1094 stories · page 8 of 11
Some of the big boys are shifting their focus away from their respiratory drugs, which could open up opportunities for Circassia to in-license them
Total revenues were still stuck in reverse gear, but the underlying picture, measured by product sales, was healthier with the figure up 8% to US$5.27bn
Investments and investor services
The focus is now on the Federal Reserve meeting later. The interest rate announcement is set for 7.00pm, UK time
Investments and investor services
Sainsbury, Superdry and Burberry are among the names in the diary for Thursday.
The UK drugs giant has been selling off lots of ‘non-core’ drugs in recent years to help keep money flowing in while it spends millions developing its pipeline
The two parties had been working together as part of a project funded by the UK government and they have agreed to continue their research
Archive
Aside from the US elections and Fed policy meeting, updates from UK blue-chip retailers J Sainsbury, Wm Morrison Supermarkets and Marks & Spencer should draw the most attention in the coming week
The launch at the Fertility Show in London at the start of November is the first step in a switch in focus brought about by new executive chairman Matthew Walls
Both Nexium, a treatment for heartburn, and Vimovo, used to treat arthritis, fall outside of AstraZeneca’s three main focus areas of cancer, cardiovascular and renal and respiratory
Deutsche Bank said the successful trial of Lynparza further increases its ‘buy’ conviction and raised its target price to 6,500p from 6,400p
Orphan drug status gives drugmakers certain benefits in order to encourage them to develop treatments for rare diseases which might otherwise lack sufficient profit motive
2019 will be an important year for the firm with the re-start of Phase I/IIa trial for RXC004, part of a niche, and potentially breakthrough group of cancer drugs
Arix is investing US$11mln in VelosBio through a Series A funding round in return for an 11.2% stake in the company
Archive
A glance at some of the day's highlights from the Proactive Investors newswire
Circassia promotes AstraZeneca’s Tudorza COPD drug in the US in return for a share of the profits, while it also has the commercial rights to another COPD drug made by AstraZeneca called Duaklir
The pound is off 0.52% against the greenback at the time of writing..
A total of 17,000 people with type-2 diabetes took part in the study
In clinical trials, 75% of the people taking the drug responded to it. In 30% of cases, Lumoxiti had a “complete durable” effect
Companies are putting together contingency plans should they not be able to move their goods freely around Europe post-Brexit
A breakthrough therapy designation is designed to expedite the development and review of medicines that are intended to treat a serious and have shown promise in early-stage clinical trials
Only one new lupus treatment has been approved in the last 60 years, so today’s news won’t come as a surprise to many scientists and doctors
“Today's approval of Bydureon BCise will enable us to offer an additional treatment option for patients with type-2 diabetes whose blood sugar levels are inadequately controlled by other glucose-lowering medicines together with diet and exe
Jefferies cut its rating on AstraZeneca to ‘hold’ from ‘buy’ but raised its target price to 6,200p from 5,942p
JPMorgan’s analysts said the target hike comes after their updated their numbers to make “further upgrades to new launch trajectories, and include risk-adjusted forecasts for three further pipeline shots on goal”
Archive
The day ahead sees Cineworld and Legal & General report their first-half results
Archive
Aside from HSBC's numbers, Prudential, L&G, Standard Life Aberdeen, and Hargreaves Lansdown are all on the results docket in the coming week
A look at some of the biggest risers and fallers in London on Thursday
The drugs giant's oncology division grew revenues by 42%
The Nasdaq on Wall Street is down over 88 points at the time of writing, at 7,420.
Archive
Three of the 10 largest London-listed companies (by capitalisation) are updating the market on Thursday. A dozen or more other household names are also expected to report.
It will receive an initial US$200mln followed by a further US$10mln, plus sales-related milestone payments
Archive
Over the five sessions in the Week Ahead, around 20% of the FTSE 100 index will report results or issue a trading update, with about half that number due on Thursday alone
Investments and investor services
We have a deluge of earnings statements from some of Britain's biggest businesses. Below we discuss the themes likely to emerge from the mid-term reporting season
It’s been a tricky period for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive
The AIM-listed fertility aid manufacturer said Matthew Walls would become chairman with immediate effect, while former chair Adam Reynolds would become a non-executive director
Lynparza and Imfinzi are likely to play an important role if AstraZeneca is to hit its target of generating annual sales of US$45bn by 2023
The drug has already been approved for later use in ovarian and breast cancer patients, but the SOLO-1 trial has sowed it could be useful as a first-line treatment
Tagrisso sales look like they will beat expectations over the coming years, but UBS has concerns that the future profits drag brought about by externalisation deals hasn’t been properly factored into estimates yet
Liberum’s Roger Franklin likes AstraZeneca, but thinks the current share price is fair, given the potential of the pipeline
AstraZeneca and Lilly’s lanabecestat drug can be added to the list of failed Alzheimer’s treatments; in fact, 99% of all drugs developed to treat the disease have failed clinical trials in the past ten years
The AIM-listed firm said Dr Trevor Nichols, who has acted as chairman of the board since January 2014, will remain on the board as non-executive director
The data showed that the combination of Lynparza and abiraterone can help patients with a specific form of prostate cancer to live for longer without their disease getting worse
Chief medical officer Dr Sean Bohen called the result disappointing
Imfinzi showed a “statically-significant” benefit to overall survival in patients with unresectable stage III non-small cell lung cancer
The US Food and Drug Administration had twice rejected AstraZeneca’s applications for Lokelma due to issues at the manufacturing plant in Texas
Investments and investor services
FTSE 100 reached a new record close on Monday after achieving it last time on Thursday
The FTSE 100-drugs giant expects product sales, which have been in decline for a while now, to return to growth this year
Footsie closed around nine points at 7,778 but it was still up 0.70% on the week - its eighth weekly gain in a row.
Archive
The day ahead includes first-quarter numbers from both blue-chip drugmaker AstraZeneca PLC and mid-cap generics firm Hikma Pharmaceuticals PLC
FTSE 250 fared better though closing ahead by around 15 points at 20,800.
Archive
Week ahead includes updates from drugs giant AstraZeneca, mobile phones operator Vodafone Group, British Gas-owner Centrica, and postal delivery firm Royal Mail Group
Its drug targeting people with chronic obstructive pulmonary disease failed to make a statistically meaningful difference
The FTSE 100 drugmaker has been selling off non-core assets in recent years as it narrows its focus on three primary areas of Oncology, Cardiovascular, Renal & Metabolism and Respiratory
The drug developer said following this acquisition, Iain Ross will hold 600,000 ordinary shares in the company, representing 0.47% of the issued share capital
A glance at some of the day's highlights from the Proactive Investors newswire
A look at some of the biggest risers and fallers in London on Tuesday
Steve Harris, Circassia’s chief executive, said he expected to see strong revenue growth in 2018
AZ’s Imfinzi was paired with tremelimumab, an immune checkpoint blocker, to treat patients with non-small cell lung cancer
Chairman Iain Ross will step back into a non-executive role following the appointment
Stocks consolidated gains at the death with bid stock Shire the best performing blue-chip
Tagrisso will now be the first treatment doctors use on lung cancer patients whose tumours have a specific mutation called an EFGR mutation
The broker is still enamoured of the UK big hitters but doesn't expect it to be plain sailing for either
Isreali drugmaker will get a US$10mln upfront payment from MedImmune in the deal
The US FDA has accepted AstraZeneca’s biologics licence application for Moxetumomab Pasudotox while the European Medicines Agency will review the company's marketing authorisation application for Lynparza
The US broker also raised its target price for the FTSE 100-listed firm to 5,600p, up from 5,075p previously, with the shares trading at 4,865p in mid-morning trading
Investments and investor services
FTSE 100 closed down 121 points at 7,042, joining other European benchmarks, which saw red
Based on current predictions, the final analysis of overall survival data from the phase III study is expected in the second-half of the year rather than the first
Investments and investor services
A look at some of today's top risers and fallers in London
Investments and investor services
The UK's blue-chip index closes up 20.84 points to 7,234.81
Investments and investor services
RELX is expected to see revenue and profit growth, whereas ConvaTec will report on what's seen as a disappointing year.
Archive
Week ahead includes the latest UK and US consumer price indexes, plus corporate updates from RELX PLC, Coca Cola HBC PLC, Shire PLC and ConvaTec PLC
AZ is one of a number of UK companies with significant US operations to update on the benefits of cutting the corporate tax rate to 21% from 35%
US workers' pay increased 2.9% year-on-year, compared to expectations of a 2.6% increase.
Archive
The day ahead includes quarterly earnings from BT and AstraZeneca as well as the US non-farm payrolls report
Britain's top tier index closed around 54 points lower at 7,533
The FTSE 100, dragged higher by the miners, got off to a strong start today, but closed juts about six points higher
Archive
Week ahead includes updates from FTSE 100 AstraZeneca PLC, BT Group PLC, Royal Dutch Shell PLC, and Unilever PLC, plus a Federal Reserve meeting and January US jobs data
The KRONOS trial showed that Astra’s PT010 inhaler can improve lung function in patients with moderate to severe chronic obstructive pulmonary disease
Now in its 20th year, the conference brings investors, analysts, and management of companies together
Investments and investor services
“If he intended it, Treasury Secretary Steven Mnuchin has done a first class job of whacking the dollar,” declared Neil Wilson at ETX Capital. .
Lynparza has been approved for use as a maintenance therapy in ovarian cancer patients, while Fasenra has been cleared as an add-on treatment for severe asthma sufferers
AstraZeneca intends to file for the trial data to be included to widen the marketing label for Turdoza
The new drug application follows positive phase II trial results
The US Food & Drug Administration gave the thumbs up overnight
Full-year earnings will still be in a bit of a Soriot-state, but won't decline as much as previously expected
After a bullish run over the past few months, European and US markets endured a rare off day on Thursday
Archive
Will Astra get into the MYSTIC? The company said not all hope was lost for its lung cancer trial, which flunked in the summer
Archive
The week ahead includes earnings from M&S, Sainsbury's, ABF, Direct Line, Wetherspoon and AstraZeneca while macro-economic announcements will be thin on the ground
Investors were more interested in Tuesday evening’s news that the US FDA had approved Calquence as a treatment for people with mantle cell lymphoma
A new formulation of Astra’s diabetes drug has been given the green light by the FDA, while it has submitted a second NDA in Japan for its Lynparza cancer drug, this time for use in breast cancer
A priority review means regulators will come to a conclusion earlier than usual and Astra expects to hear back in the first quarter of 2018
The US Food and Drug Administration has accepted a supplemental Biologics License Application (sBLA) for the treatment of certain lung cancer patients.
CS analysts say AstraZeneca is finally starting to get over the patent expiries of several blockbuster drugs, including Crestor, Seroquel and Nexium
A look at some of the biggest risers and fallers today in London
The UK blue chip index closed at 7,526, well below the session peak of 7,557.00 and close to the day’s low of 7,531.48
ShoreCap cut its price target to 4,600p from 5,154p on AstraZeneca and left its rating at ‘hold’.
"The Breakthrough Therapy Designation acknowledges not only Tagrisso's potential as a 1st-line standard of care in advanced EGFR mutation-positive NSCLC, but also the significant need for improved clinical outcomes in this disease”
"A COPD programme is now both highly attractive and economically viable"
The pipeline isn’t a pipe dream any more, so say Exane analysts
Bernstein’s analyst said they consider AstraZeneca as a “pipeline-driven, return-to-growth story”, pointing that the group has one of the fullest phase 3 trial pipelines